Nemocnica Poprad, a.s.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Diabetic eye disease3 trials
• Macular degeneration3 trials
• Heart failure2 trials
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Melanoma1 trial
• Obesity1 trial
• Ovarian cancer1 trial
• and 1 more

Phase

• Phase 36 trials
• Phase 22 trials
• Phase 11 trial

Status

• Recruiting4 trials
• Active, not recruiting2 trials
• Completed2 trials
• Terminated1 trial

Lead sponsor

• Alvotech Swiss AG1 trial
• Amgen1 trial
• Amgen Inc.1 trial
• AnaCardio AB1 trial
• Bayer1 trial
• and 4 more

Running trials

• Recruiting

  A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

  NCT07584967· Phase 2· AnaCardio AB· Source

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Amgen· Source

• Active, not recruiting

  COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  2025-523937-25-00· Phase 3· Eyepoint Inc.· Source

• Recruiting

  Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema

  2025-522231-34-00· Phase 3· Alvotech Swiss AG· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure2 recruiting
• Diabetic eye disease1 recruiting
• Macular degeneration1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

  NCT04722991· Phase 2· Bayer· Source

• Completed

  Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

  NCT04690556· Phase 3· Lupin Ltd.· Source

• Terminated

  Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

  NCT04152018· Phase 1· Pfizer· Source